And approximately 10–20% breast cancers which lack of estrogen receptor, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were classified into triple negative breast cancer (TNBC) and always posed therapeutic challenges for TNBC patients [3–6]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.